Manifold Bio Partners with Roche on Brain Shuttles for Neurological Diseases

Posted by ISPE Boston
On November 6, 2025

Launched in 2020 by serial biotech entrepreneur George Church and colleagues, Boston-based Manifold Bio has entered into a strategic collaboration and license agreement with Swiss pharma giant Roche. The new partnership will apply Manifold’s proprietary tissue-targeting BBB (blood-brain barrier) shuttle portfolio and AI-driven in vivo discovery engine to create multiple next-generation BBB shuttles for the treatment of […]

Lilly Teams with Nvidia to Build AI Supercomputer for Drug Discovery

Posted by ISPE Boston
On November 6, 2025

Pharma giant Eli Lilly has announced it is building the most powerful supercomputer owned and operated by a pharmaceutical company, in collaboration with Nvidia. The supercomputer will power an “AI factory,” a specialized computing infrastructure that manages the entire AI lifecycle. According to Kimberly Powell, vice president of health care at Nvidia, “Modern AI factories are becoming […]

Chapter Member Anniversaries: November 2025

Posted by ISPE Boston
On November 4, 2025

Please congratulate the following members celebrating milestone anniversaries in November 2025. Their dedication to ISPE, the Boston Area Chapter and the industry is applauded! Over Twenty Years Michael R. Allard Timothy J. Cotter, Cotter Brothers Corporation Timothy F. Curran, PE, NV5 Christopher P. Foran, Superior Controls Inc Michael Gorman, PM Group John J. Kelliher, Alnylam […]

Welcome New Members October 2025

Posted by ISPE Boston
On November 4, 2025

We would like to introduce the Members who joined ISPE in October 2025, welcome them to the Chapter, and encourage them (and all our members) to take advantage of the many professional development, networking and information resources available through ISPE. Fellow ISPE members are a terrific resource for help with everyday professional challenges. And the […]

Voices from the ISPE Product Show 2025

Posted by ISPE Boston
On October 28, 2025

Celebrating Innovation, Inclusion, and Community at Gillette Stadium Each year, the ISPE Product Show brings together life sciences professionals, innovators, and industry partners for a day of learning, connection, and discovery. The 2025 show at Gillette Stadium was no exception—offering everything from dynamic education sessions to immersive experiences and powerful networking moments. Below, two attendees […]

Hologic to be Acquired by Blackstone in $18 Billion Mega-Deal

Posted by ISPE Boston
On October 23, 2025

Marlborough-based Hologic has announced plans to be acquired by private equity giant Blackstone teamed with PE firm TPG, in a transaction valued at up to $18.3 billion. Hologic is a global leader in women’s health, developing innovative medical technologies that detect, diagnose and treat a variety of conditions. As reported in the Boston Globe, the […]

Invivyd Developing Vaccine-Alternative Antibody to Prevent COVID

Posted by ISPE Boston
On October 23, 2025

The FDA has cleared Invivyd’s Investigational New Drug (IND) application and provided feedback to advance the Connecticut-based company’s development program for VYD2311, a vaccine-alternative monoclonal antibody candidate for the prevention of COVID. As part of the company’s Revolution clinical program, Invivyd’s Declaration Phase 3 clinical trial will evaluate VYD2311 safety and prevention of COVID versus […]

Astria to be Acquired in $700M Deal

Posted by ISPE Boston
On October 16, 2025

Boston-based Astria is being acquired by BioCryst Pharmaceuticals in a deal worth about $700 million. Astra is focused on developing therapies for allergic and immunologic diseases. The company’s lead product candidate navenibart is an injectable, long-acting, monoclonal antibody inhibitor of plasma kallikrein for hereditary angioedema (HAE) prophylaxis and could offer significant improvements over existing injectable […]

BMS Acquires Orbital Therapeutics for $1.5 Billion

Posted by ISPE Boston
On October 16, 2025

Bristol Myers Squibb is acquiring Cambridge-based Orbital Therapeutics. Under the terms of the agreement, BMS will pay $1.5 billion in cash at closing. Orbital is a privately held biotech pioneering a new generation of RNA medicines that reprogram the immune system in vivo, enabling treatments that address the underlying biology and unique complexities of each disease. […]

Biotech 101 Kicks Off with Upstream Focus

Posted by Kathryn Tarantino
On October 7, 2025

In September, Takeda Pharmaceuticals hosted the first ISPE Biotech 101 event, “Introduction to Upstream Bioprocessing”. The session drew over 50 attendees, including students from local universities, emerging leaders, and industry professionals. Minhazuddin Mohammed and Grace Lee co-presented an overview of upstream manufacturing, highlighting key design components of different types of bioreactors, along with important economic […]

Page 1 of 12112 3 ›»